يعرض 1,281 - 1,300 نتائج من 18,095 نتيجة بحث عن 'significantly ((((linear decrease) OR (a decrease))) OR (((teer decrease) OR (greatest decrease))))', وقت الاستعلام: 0.83s تنقيح النتائج
  1. 1281
  2. 1282
  3. 1283
  4. 1284
  5. 1285
  6. 1286

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> حسب Chang Seok Han (21814121)

    منشور في 2025
    "…In addition, genetic variation in age-related plasticity in exploration contributed to a decrease in the magnitude of genetic correlations during the adult stage. …"
  7. 1287
  8. 1288
  9. 1289
  10. 1290
  11. 1291
  12. 1292
  13. 1293
  14. 1294
  15. 1295
  16. 1296
  17. 1297
  18. 1298
  19. 1299

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  20. 1300

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"